Disease · MONDO_0005492
urticaria
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. urticaria. Diseases, record MONDO_0005492. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005492
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Approval, for 18 of its 36 drugs, from DailyMed, EMA Human Drugs and PMDA
- Open Targets
Drugs36
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| OMALIZUMAB | CHEMBL1201589 | Antibody | Approval | DailyMed and EMA Human Drugs | 9 | 6 | 6 | Drugs and targets |
| DESLORATADINE | CHEMBL1172 | Small molecule | Approval | DailyMed, EMA Human Drugs and PMDA | 23 | 4 | 4 | Drugs and targets |
| EPINASTINE HYDROCHLORIDE | CHEMBL1200491 | Small molecule | Approval | PMDA | 4 | 3 | 3 | Drugs and targets |
| BILASTINE | CHEMBL1742423 | Small molecule | Approval | PMDA | 3 | 2 | 2 | Drugs and targets |
| LEVOCETIRIZINE DIHYDROCHLORIDE | CHEMBL1201190 | Small molecule | Approval | DailyMed and PMDA | 27 | 1 | 1 | Drugs and targets |
| CETIRIZINE HYDROCHLORIDE | CHEMBL1607273 | Small molecule | Approval | DailyMed | 10 | 1 | 1 | Drugs and targets |
| LORATADINE | CHEMBL998 | Small molecule | Approval | DailyMed | 2 | 1 | 1 | Drugs and targets |
| EPINEPHRINE | CHEMBL679 | Small molecule | Approval | DailyMed | 5 | 0 | 0 | Drugs and targets |
| FEXOFENADINE HYDROCHLORIDE | CHEMBL1200618 | Small molecule | Approval | DailyMed and PMDA | 3 | 0 | 0 | Drugs and targets |
| CARBINOXAMINE MALEATE | CHEMBL1200974 | Small molecule | Approval | DailyMed | 2 | 0 | 0 | Drugs and targets |
1 to 10 of 36
See all 36 drugsTargets20
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| HRH1 | Histamine H1 receptor | 19 | Histamine H1 receptor agonist; Histamine H1 receptor antagonist; Histamine H1 receptor inverse agonist | Approval | https://conductscience.org/library/genes/3269 | Drugs and targets |
| ADRA1A | Adrenergic receptor | 1 | Adrenergic receptor agonist | Approval | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor | 1 | Adrenergic receptor agonist | Approval | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor | 1 | Adrenergic receptor agonist | Approval | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRA2A | Adrenergic receptor | 1 | Adrenergic receptor agonist | Approval | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor | 1 | Adrenergic receptor agonist | Approval | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor | 1 | Adrenergic receptor agonist | Approval | https://conductscience.org/library/genes/152 | Drugs and targets |
| ADRB1 | Adrenergic receptor | 1 | Adrenergic receptor agonist | Approval | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Adrenergic receptor | 1 | Adrenergic receptor agonist | Approval | https://conductscience.org/library/genes/154 | Drugs and targets |
| ADRB3 | Adrenergic receptor | 1 | Adrenergic receptor agonist | Approval | https://conductscience.org/library/genes/155 | Drugs and targets |
1 to 10 of 20
See all 20 targetsTrials34
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00761527 | Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup in Filipino Children (Study P05634) | 2,980 | 2012-03-01 | Rhinitis, Allergic, Seasonal, Rhinitis, Allergic, Perennial, Urticaria | DESLORATADINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00536380 | Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849) | Phase 4 | 314 | 2010-05-03 | Chronic Idiopathic Urticaria | DESLORATADINE | Its record names the disease | ClinicalTrials.gov |
| NCT02935699 | Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria | Phase 3 | 262 | 2019-11-27 | Acute Urticaria | CETIRIZINE, DIPHENHYDRAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT01916967 | An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201) | Phase 3 | 239 | 2014-10-30 | Urticaria | DESLORATADINE | Its record names the disease | ClinicalTrials.gov |
| NCT00619801 | Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin | Phase 3 | 173 | 2009-09-04 | Allergic Rhinitis, Chronic Urticaria | LEVOCETIRIZINE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00866788 | A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1) | Phase 2 | 90 | 2011-09-09 | Chronic Idiopathic Urticaria | OMALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01170949 | Efficacy and Safety of Miltefosine in Antihistamine Resistant Chronic Urticaria | Phase 2 | 76 | 2016-12-26 | Chronic Urticaria | MILTEFOSINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00481676 | Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria | Phase 2 | 49 | 2011-10-21 | Chronic Urticaria | OMALIZUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03436797 | A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria | Phase 2 | 47 | 2024-01-23 | Chronic Urticaria | LIRENTELIMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02023164 | Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria | Phase 3 | 36 | 2024-02-09 | Acute Urticaria | CETIRIZINE, DIPHENHYDRAMINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 34
See all 34 trialsComparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Test Drug vs Control: Number of Patients Who Needed to Return to Treatment Center | 7 of 127 | 19 of 135 | 262 | NCT02935699 | Trial comparisons |
| Test Drug vs Control: deaths from any cause | 0 of 127 | 0 of 135 | 262 | NCT02935699 | Trial comparisons |
| Test Drug vs Control: serious adverse events | 0 of 127 | 1 of 135 | 262 | NCT02935699 | Trial comparisons |
| Levocetirizine vs Placebo: serious adverse events | 1 of 114 | 0 of 59 | 173 | NCT00619801 | Trial comparisons |
| Miltefosine vs Placebo: serious adverse events | 0 of 50 | 0 of 26 | 76 | NCT01170949 | Trial comparisons |
| AK002 Main Study vs AK002 Extended Dosing: deaths from any cause | 1 of 47 | 0 of 5 | 52 | NCT03436797 | Trial comparisons |
| AK002 Main Study vs AK002 Extended Dosing: serious adverse events | 4 of 47 | 1 of 5 | 52 | NCT03436797 | Trial comparisons |
| Omalizumab 75-375 mg vs Placebo to Omalizumab: serious adverse events | 0 of 27 | 2 of 22 | 49 | NCT00481676 | Trial comparisons |
| Active vs Placebo: deaths from any cause | 0 of 19 | 0 of 19 | 38 | NCT04853992 | Trial comparisons |
| Active vs Placebo: serious adverse events | 0 of 19 | 0 of 19 | 38 | NCT04853992 | Trial comparisons |
1 to 10 of 12
See all 12 comparisons in its trialsPapers from its trials11
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005492
GET https://conductscience.org/api/diseases/v1/MONDO_0005492/drugs?page=2